| Literature DB >> 25214844 |
Kei Nakajima1, Eiichiro Kanda2, Ami Hosobuchi1, Kaname Suwa3.
Abstract
Hearing loss leads to impaired social functioning and quality of life. Hearing loss is also associated with sleeping disorders and cardiometabolic risk factors. Here, we determined whether subclinical hearing loss is associated with sleep duration and cardiometabolic risk factors in a cross-sectional and longitudinal study of healthy Japanese general population. 48,091 men and women aged 20-79 years who underwent medical checkups were included in a cross-sectional study, and 6,674 were included in an 8-year longitudinal study. The prevalence of audiometrically determined hearing loss (>25 dB) at 4000 and 1000 Hz increased significantly with increasing sleep duration in any age strata. Logistic regression analysis showed that compared with reference sleep duration (6 h) longer sleep duration (≥8 h) was significantly associated with hearing loss, even after adjusting for potential confounding factors. Simultaneously, hearing loss was significantly associated with male sex, diabetes, and no habitual exercise. In the longitudinal study, the risk of longer sleep duration (≥8 h) after 8 years was significantly greater in subjects with hearing loss at 4000 Hz at baseline. In conclusion, current results suggest a potential association of subclinical hearing loss with longer sleep duration and cardiometabolic risk factors in a Japanese general population.Entities:
Year: 2014 PMID: 25214844 PMCID: PMC4158149 DOI: 10.1155/2014/218218
Source DB: PubMed Journal: Int J Otolaryngol ISSN: 1687-9201
Figure 1Exclusion criteria and subject disposition.
Clinical characteristics of subjects according to the five sleep duration categories.
| Five categories by sleep duration | Total | ≤5 h | 6 h | 7 h | 8 h | ≥9 h |
|---|---|---|---|---|---|---|
|
| 48,091 | 5,049 (10.5) | 22,386 (46.5) | 15,106 (31.4) | 5,176 (10.8) | 374 (0.8) |
| Age, years | 42.3 (12.1) | 39.7 (11.2) | 41.0 (11.7) | 43.4 (12.3) | 46.3 (12.8) | 49.1 (15.5) |
| Men, | 33,026 (68.7) | 3,208 (63.5) | 14,793 (66.1) | 10,767 (71.3) | 3,965 (76.6) | 293 (78.3) |
| BMI, kg/m2 | 23.5 (3.6) | 23.7 (3.9) | 23.5 (3.7) | 23.4 (3.4) | 23.5 (3.5) | 23.6 (3.5) |
| Systolic blood pressure, mmHg | 123 (17.3) | 121 (16.7) | 122 (16.9) | 124 (17.5) | 127 (18.4) | 128 (18.5) |
| Diastolic blood pressure, mmHg | 75 (13.3) | 74 (13.5) | 74 (13.1) | 75 (13.5) | 77 (13.3) | 77 (13.7) |
| Total cholesterol, mg/dL | 199 (35.5) | 198 (35.7) | 199 (35.5) | 199 (35.2) | 201 (35.7) | 198 (38.8) |
| Triglyceride, mg/dL | 96 (64–153) | 88 (59–146) | 93 (62–148) | 100 (67–157) | 107 (70–170) | 103 (73–169) |
| HDL cholesterol, mg/dL | 61.4 (15.5) | 61.9 (15.6) | 61.5 (15.6) | 61.2 (15.4) | 61.1 (15.9) | 59.0 (15.1) |
| HbA1c, %, NGSP | 5.5 (0.7) | 5.5 (0.8) | 5.5 (0.7) | 5.5 (0.7) | 5.6 (0.8) | 5.7 (1.1) |
| White blood cell, ×102/ | 65.2 (17.6) | 66.5 (18.5) | 64.8 (17.4) | 65.0 (17.6) | 66.3 (18.1) | 67.3 (19.4) |
| Past history of CVD, | 711 (1.5) | 72 (1.4) | 301 (1.3) | 229 (1.5) | 100 (1.9) | 9 (2.4) |
| Complication | ||||||
| Hypertension, | 3,697 (7.7) | 264 (5.2) | 1,436 (6.4) | 1,325 (8.8) | 623 (12.0) | 49 (13.1) |
| Dyslipidemia, | 2,187 (4.5) | 164 (3.2) | 969 (4.3) | 756 (5.0) | 280 (5.4) | 18 (4.8) |
| Diabetes, | 1,402 (2.9) | 106 (2.1) | 580 (2.6) | 477 (3.2) | 217 (4.2) | 22 (5.9) |
| Subjects with high HbA1c (≥6.5%), | 2,521 (5.2) | 217 (4.3) | 1,019 (4.6) | 851 (5.6) | 397 (7.7) | 37 (9.9) |
| Alcohol consumption | ||||||
| 1~3/w/4~6/w/daily (%) | 16.7/11.6/16.9 | 17.9/8.1/12.6 | 17.7/10.9/13.7 | 15.9/13.1/19.7 | 14.3/13.9/26.4 | 11.0/8.8/30.2 |
| Smoker | ||||||
| Past/current (%) | 11.2/38.1 | 6.8/40.5 | 10.4/36.9 | 12.9/37.6 | 13.8/41.7 | 10.7/44.7 |
| Having regular exercise | ||||||
| No/occasional~1/w/≥2/w (%)∗ | 51.0/31.8/17.2 | 57.4/28.4/14.3 | 51.4/32.2/16.4 | 48.4/33.2/18.4 | 49.9/30.2/20.0 | 57.0/24.9/18.2 |
| Self-reported tinnitus, | 1,396 (2.9) | 121 (2.4) | 635 (2.8) | 457 (3.0) | 170 (3.3) | 13 (3.5) |
| Hearing loss at 4,000 Hz in the left ear, | 3,068 (6.4) | 188 (3.7) | 1,013 (4.5) | 1,100 (7.3) | 675 (13.0) | 92 (24.6) |
| Hearing loss at 4,000 Hz in the right ear, | 2,883 (6.0) | 158 (3.1) | 952 (4.3) | 1,012 (6.7) | 656 (12.7) | 105 (28.1) |
| Hearing loss at 1,000 Hz in the left ear, | 1,097 (2.3) | 90 (1.8) | 404 (1.8) | 367 (2.4) | 192 (3.7) | 44 (11.8) |
| Hearing loss at 1,000 Hz in the right ear, | 1,070 (2.2) | 81 (1.6) | 390 (1.7) | 338 (2.2) | 225 (4.3) | 36 (9.6) |
| Work duration, hour | 8.6 (1.4) | 9.2 (1.6) | 8.7 (1.4) | 8.4 (1.3) | 8.3 (1.3) | 8.1 (1.5) |
| Occupation, (%)∗ | ||||||
| Clerical workers | 21.2 | 17.5 | 22.4 | 22.5 | 17.0 | 7.2 |
| Production workers | 8.3 | 6.7 | 7.4 | 9.4 | 9.9 | 12.8 |
| Service workers | 10.6 | 11.7 | 10.8 | 9.8 | 10.2 | 15.8 |
| Managerial workers | 6.8 | 5.9 | 6.5 | 7.7 | 6.9 | 2.9 |
| Technical workers | 5.2 | 6.6 | 5.4 | 4.8 | 4.2 | 2.7 |
| Construction workers | 6.6 | 5.7 | 5.4 | 6.6 | 12.2 | 20.3 |
| Medical workers | 4.4 | 4.9 | 4.6 | 4.2 | 3.9 | 2.9 |
| Transport workers | 3.1 | 6.8 | 2.7 | 2.2 | 3.4 | 6.2 |
| Workers not classifiable or nonemployed | 33.8 | 34.1 | 34.8 | 32.9 | 32.4 | 29.1 |
| Organic solvent workers, | 1,053 (2.7) | 109 (2.6) | 427 (2.3) | 371 (3.0) | 134 (3.2) | 12 (4.0) |
The data are expressed as means (SD). Triglyceride is expressed as medians (interquartiles).
∗Total sum is not 100% in some cases because of round-off to two decimal places.
Differences in parameters and categorical values between five sleep duration categories were significant (analysis of variance/χ 2 test; past history of CVD, and medical workers, both P = 0.01 and all others, P < 0.001), except self-reported tinnitus (P = 0.06).
BMI: body mass index, HDL: high-density lipoprotein, NGSP: national glycohemoglobin standardization program, CVD: cardiovascular disease (including stroke).
Figure 2Prevalence of hearing loss according to age group. The number of subjects is shown under the column for hearing loss at 4000 Hz in the left ear (top-left panel). The numbers of subjects included in the other panels were identical. The percentage (%) above the column expresses the average of prevalence of hearing loss according to the age group. The prevalence of hearing loss at 4000 Hz, but not at 1000 Hz, increased significantly with increasing sleep duration in most age groups (χ 2 test). Left ear at 4000 Hz: 20–39 years, P = 0.002; all other age groups, P < 0.001. Right ear at 4000 Hz: all age groups, P < 0.001. Left ear at 1000 Hz: 20–39 years, P = 0.51; 40–49 years, P = 0.20; 50–59 years, P = 0.08; 60–79 years, P < 0.001. Right ear at 1000 Hz: 20–39 years, P = 0.34; 40–49 years, P = 0.13; 50–59 years, P < 0.001; 60–79 years, P < 0.001. y.o.: years old.
Odds ratios of each sleep duration for hearing loss.
| Frequency | Sleep durations | ≤5 h | 6 h | 7 h | 8 h | ≥9 h |
|---|---|---|---|---|---|---|
| 4,000 Hz | ||||||
| Model 1 | 1 | 1.27 (1.10–1.46)‡ | 2.06 (1.79–2.36)‡ | 3.92 (3.39–4.54)‡ | 8.38 (6.50–10.8)‡ | |
| Model 2 | a | 1 | 1.04 (0.90–1.21) | 1.17 (1.01–1.37)∗ | 1.38 (1.17–1.64)‡ | 1.82 (1.32–2.50)‡ |
| b | 0.98 (0.84–1.14) | 1 | 1.11 (1.01–1.21)∗ | 1.30 (1.16–1.45)‡ | 1.72 (1.28–2.31)‡ | |
| Model 3 | 1 | 1.07 (0.90–1.27) | 1.20 (1.01–1.43)∗ | 1.36 (1.13–1.64)† | 1.75 (1.22–2.50)† | |
| 1,000 Hz | ||||||
| Model 1 | 1 | 1.08 (0.89–1.31) | 1.42 (1.17–1.73)‡ | 2.41 (1.96–2.97)‡ | 6.80 (4.88–9.48)‡ | |
| Model 2 | a | 1 | 0.93 (0.77–1.14) | 0.95 (0.77–1.16) | 1.13 (0.90–1.41) | 2.06 (1.43–2.97)‡ |
| b | 1.07 (0.88–1.31) | 1 | 1.02 (0.90–1.15) | 1.21 (1.04–1.41)∗ | 2.21 (1.60–3.07)‡ | |
| Model 3 | 1 | 1.00 (0.80–1.24) | 1.00 (0.79–1.25) | 1.16 (0.90–1.49) | 2.20 (1.47–3.29)‡ |
*P < 0.05, † P < 0.01, and ‡ P < 0.001.
The number of subjects in each group is the same as that in Table 1.
Hearing loss was defined as >25 dB hearing level in the right and/or left sides of ear.
Model 1: unadjusted.
Model 2: adjusted for age, sex, smoking, alcohol consumption, and having regular exercise, quartile of white blood cell counts, six tiles of body mass index, and past history of cardiovascular disease, complications (hypertension, dyslipidemia, and diabetes), self-reported tinnitus, working duration, and occupation.
The reference sleep duration was ≤5 h in Model 2a and 6 h in Model 2b.
Model 3: Model 2a plus adjustments for organic solvent work (available n = 39,691).
Odds ratio of cardiovascular risk factors for hearing loss.
| Models | 4,000 Hz | 1,000 Hz | ||
|---|---|---|---|---|
| Unadjusted | Multivariate adjusted | Unadjusted | Multivariate adjusted | |
| Gender | ||||
| Men (versus women) | 5.69 (5.07–6.37)‡ | 4.47 (3.87–5.15)‡ | 1.22 (1.09–1.36)‡ | 1.18 (1.01–1.37)∗ |
| Body mass index six categories | ||||
| ≤19.0 kg/m2 | 0.73 (0.63–0.86)‡ | 1.22 (1.02–1.47)∗ | 0.98 (0.79–1.20) | 1.23 (0.99–1.53) |
| 19.1–21.0 kg/m2 | 0.80 (0.71–0.89)‡ | 1.06 (0.93–1.20) | 0.81 (0.69–0.96)∗ | 0.94 (0.80–1.11) |
| 21.1–22.9 kg/m2 | 1 | 1 | 1 | 1 |
| 23.0–24.9 kg/m2 | 1.37 (1.25–1.50)‡ | 1.05 (0.94–1.17) | 1.05 (0.91–1.21) | 0.89 (0.77–1.03) |
| 25.0–26.9 kg/m2 | 1.46 (1.32–1.62)‡ | 1.06 (0.95–1.19) | 1.10 (0.94–1.28) | 0.89 (0.76–1.05) |
| ≥27.0 kg/m2 | 1.00 (0.90–1.11) | 0.95 (0.84–1.08) | 0.88 (0.74–1.03) | 0.88 (0.74–1.05) |
| White blood cell | ||||
| <25% tile | 1 | 1 | 1 | 1 |
| 25–49.9% tile | 1.29 (1.17–1.42)‡ | 1.08 (0.96–1.21) | 1.15 (1.00–1.33) | 1.10 (0.95–1.28) |
| 50–75% tile | 1.38 (1.25–1.52)‡ | 1.07 (0.95–1.19) | 1.13 (0.98–1.31) | 1.07 (0.92–1.24) |
| >75% tile (≥88.9 × 102/ | 1.67 (1.52–1.83)‡ | 1.15 (1.03–1.29)∗ | 1.18 (1.02–1.36)∗ | 1.08 (0.92–1.26) |
| Past history of cardiovascular diseasea,b | 2.08 (1.70–2.55)‡ | 1.08 (0.85–1.36) | 1.91 (1.40–2.58)‡ | 1.15 (0.83–1.58) |
| Complication of | ||||
| Hypertensionb | 3.14 (2.85–3.45)‡ | 1.00 (0.90–1.11) | 2.46 (2.15–2.81)‡ | 1.07 (0.92–1.23) |
| Dyslipidemiab | 1.27 (1.10–1.46)† | 0.81 (0.70–0.95)† | 1.51 (1.24–1.84)‡ | 1.00 (0.82–1.23) |
| Diabetesb | 3.71 (3.27–4.21)‡ | 1.53 (1.32–1.76)‡ | 3.06 (2.54–3.68)‡ | 1.56 (1.28–1.90)‡ |
| Tinnitus | ||||
| Presentb | 4.51 (3.99–5.09)‡ | 3.13 (2.71–3.62)‡ | 3.13 (2.60–3.77)‡ | 2.03 (1.67–2.47)‡ |
| Smoking | ||||
| No smoker | 1 | 1 | 1 | 1 |
| Past smoker | 1.89 (1.71–2.09)‡ | 0.98 (0.87–1.11) | 1.19 (1.02–1.39) | 0.96 (0.81–1.13) |
| Current smoker | 2.04 (1.90–2.18)‡ | 1.29 (1.18–1.41)‡ | 1.15 (1.04–1.28)† | 1.08 (0.95–1.22) |
| Alcohol consumption | ||||
| No drinker | 1 | 1 | 1 | 1 |
| Occasional drinker | 0.54 (0.48–0.60)‡ | 0.95 (0.84–1.07) | 0.49 (0.42–0.56)‡ | 0.87 (0.74–1.01) |
| 1~3/week drinker | 0.77 (0.69–0.86)‡ | 0.85 (0.75–0.96)† | 0.62 (0.52–0.73)‡ | 0.85 (0.72–1.01) |
| 4~6/week drinker | 1.31 (1.18–1.46)‡ | 0.93 (0.83–1.06) | 0.82 (0.70–0.97)∗ | 0.82 (0.69–0.98)∗ |
| Daily drinker | 2.40 (2.21–2.62)‡ | 1.17 (1.05–1.30)† | 1.37 (1.20–1.55)‡ | 1.04 (0.90–1.20) |
| Exercise | ||||
| ≥2/week exerciser | 1 | 1 | 1 | 1 |
| 1/week exerciser | 0.94 (0.84–1.05) | 0.99 (0.87–1.13) | 0.83 (0.71–0.99)∗ | 0.93 (0.78–1.10) |
| Occasional exerciser | 0.88 (0.78–0.99)∗ | 1.12 (0.97–1.29) | 0.72 (0.59–0.87)‡ | 0.99 (0.81–1.21) |
| No exerciser | 1.13 (1.03–1.23)∗ | 1.18 (1.06–1.31)† | 1.10 (0.96–1.25) | 1.18 (1.02–1.36)∗ |
| Work duration | ||||
| ≤6 h | 1 | 1 | 1 | 1 |
| 7 h | 1.58 (1.34–1.85)‡ | 1.05 (0.86–1.29) | 0.89 (0.73–1.10) | 0.90 (0.72–1.11) |
| 8 h | 1.27 (1.12–1.45)‡ | 1.00 (0.85–1.18) | 0.61 (0.52–0.70)‡ | 0.85 (0.71–1.01) |
| 9 h | 0.96 (0.83–1.11) | 0.87 (0.72–1.06) | 0.45 (0.37–0.55)‡ | 0.76 (0.61–0.95)∗ |
| 10 h | 0.93 (0.79–1.08) | 0.92 (0.76–1.11) | 0.40 (0.32–0.49)‡ | 0.71 (0.56–0.90)† |
| ≥11 h | 0.70 (0.60–0.82)‡ | 0.87 (0.72–1.06) | 0.29 (0.24–0.36)‡ | 0.62 (0.48–0.79)‡ |
*P < 0.05, † P < 0.01, and ‡ P < 0.001.
aCardiovascular disease including heart disease and stroke.
bPresent versus absent.
Confounding factors in multivariate adjustments include those listed in Model 2a of Table 2.
Numbers in exercise express the times of exercise (>30 min per session).
Baseline clinical characteristics of subjects and prevalence of longer sleep duration eight years later in the longitudinal study.
| Categories by sleep duration | Total | ≤5 h | 6 h | 7 h |
|
|---|---|---|---|---|---|
|
| 6,774 | 450 (10.5) | 3,063 (46.6) | 3,261 (31.4) | — |
| Age (years) | 41.6 ± 9.0 | 40.2 ± 9.5 | 41.2 ± 9.1 | 42.1 ± 8.8 | <0.0001 |
| Men, | 4,639 (68.5) | 268 (59.6) | 1,959 (64.0) | 2,412 (74.0) | <0.0001 |
| BMI (kg/m2) | 23.2 ± 3.3 | 23.3 ± 3.6 | 23.3 ± 3.4 | 23.2 ± 3.1 | 0.67 |
| Systolic blood pressure (mmHg) | 123 ± 16.0 | 122 ± 15.7 | 123 ± 16.0 | 124 ± 16.0 | <0.0001 |
| Diastolic blood pressure (mmHg) | 74 ± 12.2 | 72 ± 12.2 | 74 ± 12.2 | 75 ± 12.1 | <0.0001 |
| HbA1c (%, NGSP) | 5.4 ± 0.6 | 5.4 ± 0.8 | 5.4 ± 0.6 | 5.4 ± 0.6 | 0.39 |
| White blood cell (×102/ | 65.0 ± 17.4 | 64.0 ± 16.4 | 64.9 ± 17.7 | 65.3 ± 17.1 | 0.32 |
| Past history of CVD, | 84 (1.2) | 10 (2.2) | 36 (1.2) | 38 (1.2) | 0.15 |
| Medication for | |||||
| Hypertension, | 259 (3.8) | 13 (2.9) | 113 (3.7) | 133 (4.1) | 0.41 |
| Dyslipidemia, | 71 (1.0) | 0 (0.0) | 33 (1.1) | 38 (1.2) | —∗ |
| Diabetes, | 66 (1.0) | 5 (1.1) | 32 (1.0) | 29 (0.9) | —∗ |
| Alcohol consumption | |||||
| No~occasional/1~3/w/4~6/w/daily (%)∗ | 45/23/11/22 | 48/26/8/17 | 48/23/11/18 | 41/22/12/26 | <0.0001 |
| Current smoker, | 2,606 (38.5) | 171 (38.0) | 1,120 (36.6) | 1,315 (40.3) | 0.009 |
| Having regular exercise | |||||
| No/occasional/1/w/≥2/w (%)∗ | 50/13/18/20 | 54/14/14/18 | 50/13/18/20 | 47/14/19/20 | 0.09 |
| Hearing loss at least in one ear at 4,000 Hz, | 457 (6.7) | 19 (4.2) | 175 (5.7) | 263 (8.1) | <0.0001 |
| Hearing loss at least in one ear at 1,000 Hz, | 168 (2.5) | 8 (1.8) | 77 (2.5) | 83 (2.5) | 0.61 |
| Work duration (hour) (available | 8.5 ± 1.2 | 8.9 ± 1.4 | 8.6 ± 1.2 | 8.4 ± 1.1 | <0.0001 |
| Prevalence of longer sleep duration eight years later, | 452 (6.7) | 11 (2.4) | 109 (3.6) | 332 (10.2) | <0.0001 |
The data are expressed as means ± SD. Triglyceride is expressed as medians (interquartiles).
Individuals with longer sleep duration (≥8 hour) at baseline were not enrolled in the longitudinal study.
∗Total sum is not 100% in some cases because of decimal points.
BMI: body mass index, HDL: high-density lipoprotein, NGSP: national glycohemoglobin standardization program, and CVD: cardiovascular disease (including stroke).
Relative risks for longer sleep duration according to baseline hearing loss.
| Baseline hearing loss at 4000 Hz | Baseline hearing loss at 1000 Hz | |||
|---|---|---|---|---|
| Absent | Present | Absent | Present | |
| Baseline | 6317 | 457 | 6606 | 168 |
| Long-time sleep in 2008 | 394 | 58 | 433 | 19 |
|
| ||||
| Relative risk (95% CI) | Relative risk (95% CI) | |||
|
| ||||
| Model 1 | 1 | 2.19 (1.63–2.93)† | 1 | 1.82 (1.12–2.96)∗ |
| Model 2 | 1 | 1.56 (1.14–2.13)∗ | 1 | 1.50 (0.92–2.47) |
| Model 3 | 1 | 1.53 (1.11–2.10)∗ | 1 | 1.52 (0.92–2.50) |
*P < 0.01 and † P < 0.001.
Longer sleep duration at the time point of 9 years was defined as ≥8 h. Hearing loss was defined as loss of hearing of >25 dB in at least one ear.
The number of subjects in each group is the same as that in Table 3.
Model 1: unadjusted.
Model 2: adjusted for age, sex, smoking, alcohol consumption, and regular exercise.
Model 3: Model 2 plus baseline medications for hypertension, dyslipidemia, and diabetes; baseline past history of cardiovascular disease; and baseline body mass index and white blood cell count (total available n = 6250).